ביוטיים תדווח על התוצאות הכספיות של הרבעון השלישי של 2018 ב-8 בנובמבר 2018

אלמידה, קליפורניה, 30 אוקטובר 2018, (BUSINESS WIRE):

ביוטיים, BioTime, Inc. (NYSE American ו-TASE: BTX), חברת ביוטק בשלב הקליני שמתמקדת במחלות ניווניות, הודיעה היום שהיא תדווח על התוצאות הכספיות והתפעוליות שלה ברבעון השלישי של 2018 ביום חמישי, ה-8 בנובמבר 2018, אחר סגירת השווקים הפיננסיים האמריקנים. הנהלת ביוטיים גם תארח שיחת ועידה ושידור אינטרנט ביום חמישי, ה-8 בנובמבר 2018, בשעה 16:30 שעון החוף המזרחי/ 13:30 שעון החוף המערבי כדי לדון בתוצאות הכספיות שלה ברבעון השלישי של 2018 וכדי למסור עדכון עסקי.

BioTime to Report Third Quarter 2018 Financial Results on November 8^th, 2018

ALAMEDA, Calif., 30 OCT 2018, (BUSINESS WIRE):

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its third quarter 2018 financial and operating results on Thursday, November 8^th, 2018, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, November 8^th, 2018, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2018 financial results and to provide a business update.

Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and should request the “BioTime Inc. Call”. A live webcast of the conference call will be available online in the Investors section of BioTime’s website. A replay of the webcast will be available on BioTime’s website for 30 days and a telephone replay will be available through November 15^th, 2018, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and entering conference ID number 8658619.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime’s lead cell replacement product candidate is OpRegen^®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime’s lead cell delivery clinical program is Renevia^®, an investigational medical device being developed as an alternative for whole adipose tissue transfer procedures. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.

Regarding the dividend distribution of AgeX Therapeutics, Inc. that we have previously announced, and with respect to certain index funds in Israel, we have been informed that a third party has committed to purchase any and all shares of AgeX from all index funds in Israel at a price of $2.80 per share and up to a maximum dollar amount of $2.5 million.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+. To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com.